Mersana Therapeutics, Inc.
MRSNNASDAQHealthcare
$29.08
+$0.00(+0.00%)
Market Cap$145363650
P/E Ratio—
52W High$30.39
52W Low$5.21
Mersana Therapeutics, Inc. (MRSN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MRSN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $40.50M | $36.85M | $26.58M | $0.04M | $0.83M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $67.04M |
| Gross Profit | $40.50M | $36.85M | $26.58M | $0.04M | ($66.21M) |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $73.02M | $148.27M | $173.38M | $132.01M | $67.04M |
| G&A Expenses | $40.81M | $59.54M | $56.96M | $36.89M | $21.90M |
| Total Operating Expenses | $113.83M | $207.81M | $230.35M | $168.90M | $88.94M |
| Operating Income | ($73.34M) | ($170.96M) | ($203.77M) | ($168.86M) | ($155.15M) |
| Operating Margin %(computed) | -181.09% | -463.86% | -766.59% | — | — |
| Interest Income | $8.44M | $12.07M | $2.88M | $0.07M | $0.42M |
| Interest Expense | $3.87M | $4.07M | $3.33M | $1.27M | $0.36M |
| Income Before Tax | ($68.77M) | ($171.67M) | ($204.21M) | ($170.06M) | ($88.05M) |
| Income Tax Expense | $0.42M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($69.19M) | ($171.67M) | ($204.21M) | ($170.06M) | ($88.05M) |
| Net Margin %(computed) | -170.86% | -465.80% | -768.26% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-14.12 | $-36.96 | $-54.51 | $-60.24 | $-35.80 |
| Wtd Avg Shares | 4.90M | 4.64M | 3.75M | 2.82M | 2.46M |
| EBITDA | ($63.27M) | ($166.08M) | ($199.96M) | ($167.94M) | ($87.10M) |
| EBITDA Margin %(computed) | -156.24% | -450.63% | -752.26% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Mersana Therapeutics, Inc. data
About Mersana Therapeutics, Inc. (MRSN) Income Statement
Mersana Therapeutics, Inc. (MRSN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, MRSN reported revenue of $0.04B, gross profit of $0.04B (gross margin 100.00%), and net income of ($0.07B) — a net profit margin of -170.86%.
Frequently asked questions
MRSN · 4 questionsMersana Therapeutics, Inc. (MRSN) reported revenue of $0.04B for 2024, up 9.9% year-over-year.
MRSN revenueMRSN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09